Certis Oncology CertisAI Platform

Certis Oncology, a San Diego-based precision oncology and translational science company, has launched CertisAI, a predictive medicine platform that uses data, statistical algorithms, and multivariate machine learning to predict drug efficacy based on gene expression biomarkers. CertisAI can replace many traditional discovery screening studies with in silico predictions such as identifying biomarkers predictive of therapeutic response; uncovering biological pathway mechanisms of action; ranking cancer types most likely to respond to a lead candidate; and elucidating synergistic potential of combinatorial therapies. Researchers can also use the platform to select optimal cancer models for in vitro and in vivo validations studies, develop patient stratification strategies for clinical trials, and prioritize candidate in compound libraries and/or assess the value of intellectual property, the company said.